Unique ID issued by UMIN | UMIN000058639 |
---|---|
Receipt number | R000067060 |
Scientific Title | A prospective observational study of image-guided proton therapy for early-stage lung cancer |
Date of disclosure of the study information | 2025/07/31 |
Last modified on | 2025/07/29 20:19:14 |
A prospective observational study of image-guided proton therapy for early-stage lung cancer
A prospective observational study of image-guided proton therapy for early-stage lung cancer
A prospective observational study of image-guided proton therapy for early-stage lung cancer
A prospective observational study of image-guided proton therapy for early-stage lung cancer
Japan |
early-stage lung cancer
Pneumology | Radiology |
Malignancy
NO
To develop future treatments for early-stage lung cancer, we will conduct data registration and clinical practice (covered by insurance) as a prospective observational study in general practice, and conduct detailed analysis using our own institution's medical information.
Safety,Efficacy
5 year overall survival
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1. Patients with non-small cell lung cancer diagnosed by histology or cytology, or those with a clinical diagnosis of lung cancer
2. Patients with clinical stage IA-II diagnosed by chest and abdominal CT, head MRI, or FDG-PET within 56 days (TNM classification: 2024, UICC 9th edition).
3. Males and females aged 20 years or older at the time of obtaining consent for treatment.
4. Patients who are able to maintain a stable position during irradiation.
5. Patients who are judged to be able to plan a treatment that does not exceed the dose limits for adjacent organs.
6. Patients who are deemed suitable for proton therapy by the Cancer Board.
7. Patients who have received an explanation of the treatment using a consent form and have given written consent for treatment.
1. Pregnant or potentially pregnant patients
2. Patients whose wishes cannot be confirmed
3. Patients with active, refractory infections
4. Patients with psychiatric disorders or symptoms that make participation in this treatment protocol difficult
5. Patients with other serious complications (such as poorly controlled hypertension or diabetes, active gastrointestinal bleeding, etc.)
6. Patients who are deemed ineligible for this study by the researchers for medical, psychological, or other reasons other than those listed above.
200
1st name | Iwata |
Middle name | |
Last name | Hiromitsu |
Nagoya City University West Medical Center
Department of Radiation Oncology
462-8508
1-1-1 Hirate-cho, Kita-ku, Nagoya, Aichi, Japan
0529918121
h-iwa-ncu@nifty.com
1st name | Iwata |
Middle name | |
Last name | Hiromitsu |
Nagoya City University West Medical Center
Department of Radiation Oncology
462-8508
1-1-1 Hirate-cho, Kita-ku, Nagoya, Aichi, Japan
0529918121
h-iwa-ncu@nifty.com
Nagoya City University West Medical Center
None
Self funding
Nagoya City University Ethics Review Committee
1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan
052-858-7215
clinical_research@med.nagoya-cu.ac.jp
NO
2025 | Year | 07 | Month | 31 | Day |
Unpublished
Open public recruiting
2025 | Year | 07 | Month | 02 | Day |
2025 | Year | 07 | Month | 14 | Day |
2025 | Year | 07 | Month | 18 | Day |
2035 | Year | 12 | Month | 31 | Day |
Prognosis etc.
2025 | Year | 07 | Month | 29 | Day |
2025 | Year | 07 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067060